Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study

by Christian Combe, Johannes Mann, David Goldsmith, Frank Dellanna, Philippe Zaoui, Gérard London, Kris Denhaerynck, Andriy Krendyukov, Ivo Abraham, Karen MacDonald
Published 2019-03-01

Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Resu...

by Jan Galle, Werner Kleophas, Frank Dellanna, Volkmar H.R. Schmid, Claudia Forkel, Gerhard Dikta, Vera Krajewski, Winfried Fuchs, Thomas Forst, Andreas Pfützner
Published 2012-05-01

Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification

by Daniel W. Coyne, Hem N. Singh, William T. Smith, Ana Carolina Giuseppi, Jamie N. Connarn, Matthew L. Sherman, Frank Dellanna, Hartmut H. Malluche, Keith A. Hruska
Published 2019-11-01

First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis.

by Lutz Renders, Klemens Budde, Christian Rosenberger, Rachel van Swelm, Dorine Swinkels, Frank Dellanna, Werner Feuerer, Ming Wen, Christiane Erley, Birgit Bader, Claudia Sommerer, Matthias Schaier, Karoline Meurer, Louis Matis
Published 2019-01-01